Category: News

BDNG Annual Conference 2025, Harrogate

Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, Catherine H Smith, Richard B Warren, Christopher E M Griffiths, BADBIR study groupBritish Journal of Dermatology, ljaf017, https://doi.org/10.1093/bjd/ljaf017  Related Oras A Alabas, Kayleigh J...

Taltz (ixekizumab) recruitment ends on 31st July 2025

Taltz (ixekizumab) recruitment ends on 31st July 2025

Please be aware that BADBIR cannot accept any new registrations at baseline for patients starting Taltz after 31st July. Participants must have started treatment and provided consent before 1st August to be accepted. If participants signed consent and commenced Taltz...

We’ll be at the BAD Annual Meeting in Glasgow

We will be at the BAD Annual Meeting in Glasgow from the 1st to the 3rd July - come visit us at our stand!You can also attend one of our talks:- Tuesday, 1st July at 10:30 - Prof Warren & Dr Oras Alabas - Hot Topics - Update on new data to inform clinicians on use...

Changes to conventional cohort eligibility criteria

As part of the 14th Substantial Amendment for the study, there have been some changes to the eligibility criteria for patients on conventional treatments. The implementation date for Substantial Amendment 14 is 08/05/2025; these changes will affect any patients...

Taltz (ixekizumab) recruitment has restarted

If a patient recently started on Taltz meets all of our eligibility criteria, they can be recruited.We will review patients who switched from the Conventional cohort onto Taltz, where we have paused their cohort; these patients will now be able to be switched.Please...

Taltz (ixekizumab) recruitment will end on 31st July 2024

Please be aware that BADBIR cannot accept any new registrations at baseline for patients starting Taltz after 31st July. Participants must have started treatment and provided consent before 1st August to be accepted. If participants signed consent and commenced Taltz...

Recruitment open to Spevigo (spesolimab)

We are now accepting patients on Spevigo (spesolimab). Spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (GPP). BADBIR can accept registrations for patients with a GPP diagnosis.Please see the eligibility page for...